Pouyiourou, M.
Meyer, A.
Stroux, A.
Viardot, A.
La Rosée, P.
Maschmeyer, G.
Kämpfe, D.
Kahl, C.
Vucinic, V.
Monecke, A.
Hirt, C.
Weber, T.
Meissner, J.
Witzens-Harig, M.
Böttcher, S.
Schmalenberg, H.
Marks, R.
Prange-Krex, G.
Kroschinsky, F.
Hauf, E.
Keller, U.
Koch, K.
Klapper, W.
Herold, M.
Scholz, Christian W. http://orcid.org/0000-0001-6260-4086
,
Article History
Received: 17 April 2020
Accepted: 9 July 2020
First Online: 30 July 2020
Compliance with ethical standards
:
: AV has been on Advisory Boards for Amgen, Roche, Kite/Gilead, and Novartis and received travel support and speaker honoraria from Amgen, Roche, Kite/Gilead, and Janssen. PLR has been on the Advisory Board for Roche. GM has received honoraria for lectures from Gilead, Janssen Cilag, AMGEN, Merck-Serono, Bristol-Myers Squibb, and AstraZeneca and travel grants from Janssen Cilag. TW has received travel grants and has been on the Advisory Board for Roche. SB reports consulting fees from Roche and AbbVie, research funding from Roche, Janssen, AbbVie, and Celgene, and honoraria from Roche, AbbVie, Janssen, Novartis, and Becton Dickinson. HS has received speaker honoraria and has been on the Advisory Boards for Lilly, MSD, Roche, Novartis, BMS, Basilea, Merck Serono, and Servier and has received research support from Sanofi. RM has received speaker honoraria and has been on the Advisory Boards for Janssen, Merck, Eusa, Novartis, and Kite/Gilead and has received travel grants from Kite/Gilead. UK has received travel support, speaker support and speaker honoraria from Roche and travel support and speaker honoraria from Mundipharma. WK has received research grants from Roche, Takeda, Amgen and Regeneron. SWS has received speaker honoraria from Gilead, Janssen and Pfizer and has been on the Advisory Boards for Roche, Novartis, Janssen, Hexal, Gilead, Takeda, Daiichi Sankyo, Celgene, Bristol-Myers Squibb, and Merck Serono. All remaining authors have declared no conflicts of interest.
: The retrospective analysis was approved by the ethics committee of the Berlin Chamber of Physicians. The study was conducted in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki.
: As this is a retrospective analysis of patient data, no additional informed consent was required. Patient data was collected and analyzed in anonymized form. Dates of birth were provided as five-year intervals in order to avoid patient identification (i.e., 1950–1954 for a patient born in 1952).
: Not applicable.